Valisure’s CEO, amongst other industry leaders, is credited as an author in the Journal of the American Pharmacists Association paper titled, A Data-Driven Quality-Score System For Rating Drug Products And Its Implications For The Health Care Industry. The paper proposes a quality-score system driven by independent data to differentiate between the qualities of drug products produced by different manufacturers.

The quality of drug products in the United States has been a matter of growing concern. Buyers and payers of pharmaceuticals have limited insight into measures of drug-product quality. Therefore, a quality-score system driven by data collection is proposed to differentiate between the qualities of drug products produced by different manufacturers. The quality scores derived using this proposed system would be based upon public regulatory data and independently-derived chemical data. A workflow for integrating the system into procurement decisions within health care organizations is also suggested. The implementation of such a quality-score system would benefit health care organizations by including the consideration of the quality of products while also considering price as a part of the drug procurement process. Such a system would also benefit the U.S. health care industry by bringing accountability and transparency into the drug supply chain and incentivizing manufacturers to place an increased emphasis on the quality and safety of their drug products.

Read the full paper here.

Valisure’s CEO, amongst other industry leaders, is credited as an author in the Journal of the American Pharmacists Association paper titled, A Data-Driven Quality-Score System For Rating Drug Products And Its Implications For The Health Care Industry. The paper proposes a quality-score system driven by independent data to differentiate between the qualities of drug products produced by different manufacturers.

The quality of drug products in the United States has been a matter of growing concern. Buyers and payers of pharmaceuticals have limited insight into measures of drug-product quality. Therefore, a quality-score system driven by data collection is proposed to differentiate between the qualities of drug products produced by different manufacturers. The quality scores derived using this proposed system would be based upon public regulatory data and independently-derived chemical data. A workflow for integrating the system into procurement decisions within health care organizations is also suggested. The implementation of such a quality-score system would benefit health care organizations by including the consideration of the quality of products while also considering price as a part of the drug procurement process. Such a system would also benefit the U.S. health care industry by bringing accountability and transparency into the drug supply chain and incentivizing manufacturers to place an increased emphasis on the quality and safety of their drug products.

Read the full paper here.